BeiGene (BGNE) Peer Comparison
$226.71
$42.00
(22.74%)
As on 29-Jan-2025 09:30EDT
Market cap
$20,209 Mln
Revenue (TTM)
$2,459 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Edit
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
20,209 | 63,631 | 20,720 | 2,928 | 2,262 |
Revenue ($ Mln) |
2,459 | 8,446 | 4,131 | 450 | 120 |
Net Profit ($ Mln) |
-881.71 | 2,595.76 | 788.10 | -188.21 | -57.50 |
Net Margin (%) |
-25.94 | 30.73 | 19.08 | -41.86 | -144.33 |
RoE (%) |
-24.93 | 32.98 | 13.37 | -28.46 | -9.86 |
Price to Earnings |
-- | 38.95 | 26.17 | -- | -- |
Price-To-Book |
7.04 | 7.87 | 3.52 | 4.96 | 4.15 |
Income Statement ($ Mln)
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,458.78 | 2,190.23 | 21,526.00 | 398.99 | 5.90 |
|
Cost of Revenue
|
379.92 | 227.29 | 985.00 | 147.86 | 41.07 |
|
Gross Profit
|
2,078.86 | 1,962.94 | 20,541.00 | 251.13 | -35.17 |
|
Operating Expenses
|
3,286.60 | 1,984.60 | 13,838.00 | 533.25 | 48.98 |
|
Operating Profit (EBIT)
|
-1,207.74 | -21.65 | 6,703.00 | -282.12 | -84.15 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-825.84 | 85.18 | 9,164.00 | -257.10 | -88.15 |
|
Provision for Tax
|
55.87 | -747.86 | 1,320.00 | -- | -0.19 |
|
Profit after Tax (Net Income)
|
-881.71 | 833.04 | 7,844.00 | -257.10 | -87.96 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3,537.33 | 5,498.28 | 36,697.00 | 840.90 | 480.36 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
457.84 | 34.32 | 3,806.00 | 45.47 | 115.56 |
|
Current Liabilities
|
1,810.11 | 669.92 | 5,308.00 | 299.39 | 73.24 |
|
Total Liabilities
|
5,805.28 | 6,202.52 | 45,811.00 | 1,185.75 | 669.15 |
Assets ($ Mln)
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,601.86 | 1,319.42 | 17,957.00 | 135.27 | 582.69 |
|
Current Assets
|
4,203.41 | 4,883.10 | 27,854.00 | 1,050.48 | 86.46 |
|
Total Assets
|
5,805.28 | 6,202.52 | 45,811.00 | 1,185.75 | 669.15 |
|
Total Debt*
|
930.19 | 39.05 | 1,029.00 | 153.47 | 118.92 |
|
Net Current Assets
|
-- | 4,213.19 | 22,546.00 | 751.10 | 13.22 |
Cashflow ($ Mln)
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1,157.45 | -82.75 | 7,771.00 | -214.87 | -48.46 |
|
Cash Flow from Investing Activities
|
-- | -717.59 | -9,907.00 | -375.19 | -0.10 |
|
Cash from Financing Activities
|
416.48 | 279.76 | -3,919.00 | 349.89 | 40.25 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-19.74 | 17.26 | 22.38 | -28.48 | -14.45 |
|
ROE (%)
|
-24.93 | 17.36 | 22.97 | -31.41 | -17.91 |
|
ROA (%)
|
-15.19 | 15.51 | 19.34 | -23.14 | -13.14 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-35.86 | 38.03 | 36.44 | -64.44 | -1,490.27 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.00 | 0.79 | 0.31 | 0.50 | -0.21 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
0.00 | 382.34 | 80.24 | 23.17 | -7.41 |
|
EPS Growth (%)
|
-- | 3.32 | 0.85 | -6.33 | 0.10 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 52.38 | 1.71 | -10.37 | -8.69 |
|
Price / Book Value
|
-- | 7.94 | 0.36 | 3.17 | 1.59 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
2.00 | 383.16 | -0.69 | -8.69 | -14.63 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.26 | 0.01 | 0.03 | 0.18 | 0.25 |
|
Short term debt to equity ratio
|
0.20 | 0.00 | 0.00 | 0.17 | 0.03 |
|
Current Ratio
|
2.32 | 7.29 | 5.25 | 3.51 | 1.18 |
|
Quick Ratio
|
2.09 | 6.68 | 5.24 | 3.38 | 1.18 |
|
Interest Coverage
|
-- | 39.50 | 77.37 | -113.07 | -2.81 |
Operating Efficiency Ratios
| BeiGene (BGNE) | argenx SE - ADR | Genmab A/S ADS - ADR | Zai Lab - ADR | Mesoblast - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.10 | 41.51 | 31.08 | 22.41 | 355.00 |
|
Asset Turnover
|
0.42 | 0.41 | 0.53 | 0.36 | 0.01 |
|
Receivable days
|
58.81 | 117.43 | 98.74 | 70.83 | 864.85 |
|
Inventory Days
|
400.05 | 576.73 | 22.06 | 104.62 | -19.23 |
|
Payable days
|
302.94 | 472.28 | 855.46 | 264.19 | 121.02 |
|
Cash Conversion Cycle
|
155.92 | 221.88 | -734.66 | -88.74 | 724.61 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
